电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

HIV-2 (AA 390-702) 抗体

Cited in 1 publication. The 小鼠 单克隆 anti-HIV-2 antibody (Clone BDI411) (ABIN111771) specifically detects HIV-2 in WB, EIA 和 IP. The antibody is reactive with Human Immunodeficiency Virus (HIV) samples.
产品编号 ABIN111771
发货至: 中国
Contact our Customer Service for availability and price in your country. Contact Info

Our Local Distributor

中国
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
4A Biotech Co.,Ltd.
Tel +86 (0512) 65829739 传真 +86 (010) 6788 5057

Quick Overview for HIV-2 (AA 390-702) 抗体 (ABIN111771)

抗原

HIV-2

适用

Human Immunodeficiency Virus (HIV)

宿主

  • 3
  • 1
小鼠

克隆类型

  • 4
单克隆

标记

  • 4
非结合性

应用范围

  • 4
  • 4
  • 3
  • 3
  • 3
  • 3
Western Blotting (WB), Enzyme Immunoassay (EIA), Immunoprecipitation (IP)

克隆位点

BDI411
  • 抗原表位

    AA 390-702

    纯化方法

    Protein G Chromatography.

    免疫原

    Recombinant gp36, amino acids 390-702 (Art. No. BIN07)

    亚型

    IgG2a
  • 应用备注

    Suitable for use in Western blot (1: 1,000), ELISA (1: 500) and Immunoprecipitation.
    Other applications not tested.
    Optimal dilutions are dependent on conditions and should be determined by the user.

    限制

    仅限研究用
  • 浓度

    1.0 mg/mL

    缓冲液

    1X PBS, pH 7.2 containing 0.01 % Sodium Azide as preservative.

    储存液

    Sodium azide

    注意事项

    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    注意事项

    Avoid repeated freezing and thawing.

    储存条件

    -20 °C
  • Dufrasne, Lucchetti, Martin, André, Dessilly, Kabamba, Goubau, Ruelle: "Modulation of the NF-κB signaling pathway by the HIV-2 envelope glycoprotein and its incomplete BST-2 antagonism." in: Virology, Vol. 513, pp. 11-16, (2017) (PubMed).

  • 抗原

    HIV-2

    物质类

    Virus

    背景

    HIV2 infections at present, are predominantly found in west Africa where it is the dominant form of HIV. Both HIV1 and HIV2 have the same modes of transmission and are associated with similar opportunistic infections and AIDS. In persons infected with HIV2, immunodeficiency seems to develop more slowly and to be milder, but as the disease advances, HIV2 infectiousness seems to increase. Little is known about the best approach to the clinical treatment and care of patients infected with HIV2. Some drugs used to treat HIV1 are ineffective. HIV1 and HIV2 have similar gag (viral core) and pol (polymerase) regions, they have relatively dissimilar env (envelope) regions. Owing to this lack of homology in the envelope region, there is little serologic cross-reactivity of the antibodies directed against the envelope antigens of both HIV1 and HIV2. The env gp36 ectodomain is highly conserved and elicits a type-specific antibody response. Hence, most licensed diagnostic assays incorporate gp36-derived antigens to detect HIV2 specific antibodies. It is becoming important to differentiate between single infection with either HIV1 or HIV2 and dual infection.Synonyms: HIV2, Human immunodeficiency virus type 2
You are here: